The changing landscape of Multiple Myeloma therapies market
Multiple Myeloma , the second most common type of malignant cancer first being Non-Hodgkin lymphoma, is a type of cancer which is formed due to the presence of malignant plasma cells in bone marrow . Due to the vigorous proliferation of highly abnormal, unstable cells circulating via the bloodstream and lymph nodes, this eventually results in the formation of cancer cells in bone marrow outnumbering the healthy blood cells and immunoglobulins. The prevalence of Multiple Myeloma in the elderly population has contributed to the MYELOMA DRUG MARKET . It could be due to the demographic burden as the proportion of the geriatric population in the country will be greater compared to that of the millennials. Myeloma incidence is strongly related to age, with the highest incidence rates being in older people. According to the World Bank in 2018, the older population was about 16% of the total population in the U.S. But according to the United States Census Bureau the increasing